Abstract PS5-01-22: Efficacy of second- or third-line Tucatinib, Trastuzumab, and Capecitabine (TTC) following trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic breast cancer: A multicenter French cohort study
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Authors: J. S. Frenel, A. de Nonnevile, C. Guerin-Charbonnel, J. Zeghondy, L. Mathiot, A. Mailliez, F. Poumeaud, N. Isambert, M. Arnedos, F. Le Du, L. Galland, R. Kabirian, S. Guiu, L. Poestch, E. Deluche, F. Cherifi, F. Dalenc, E. Volant, B. Pistilli, T. San, T. Bachelot, A. Patsouris, F. Bocquet, L. Larrouquere, D. Loirat
Institutions: Institut de Cancérologie de l'Ouest, Institut Paoli-Calmettes, Institut Gustave Roussy, Fondation Gustave Roussy, Centre Oscar Lambret, Centre Hospitalier Universitaire de Poitiers, Centre Eugène Marquis, Centre Georges François Leclerc, Institut Curie, Polyclinique Bordeaux Nord Aquitaine, Centre Hospitalier Universitaire de Limoges, Centre François Baclesse, Centre Léon Bérard
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129259230
Cites:
Cited by:
Related to: